جولای 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics و GenScript ProBio در حال امضای قراردادی برای توسعه و تولید پلاسمید و ناقل ویروس برای اولین خط لوله پلت فرم پیشرفته CAR-T ACT Therapeutics هستند که همچنین برای تولید مواد خام راه اندازی خواهد شد. برای خطوط لوله بعدی ACT Therapeutics. این قرارداد تولید پلاسمیدها و ناقل های ویروس برای اولین خط لوله پلت فرم پیشرفته CAR-T ACT Therapeutics را پوشش می دهد.
در نتیجه این توافق، GenScript ProBio به یک شریک جهانی ارتقا یافته است که می تواند از پلتفرم های ACT برای درمان های ACT پشتیبانی کند.
پلتفرم ACT یک فناوری سلول درمانی و ژن درمانی نسل بعدی است که آنتی ژن های سرطانی را با قرار دادن ژن هایی که برای هدف قرار دادن آن آنتی ژن ها در سلول های ایمنی طراحی شده اند، هدف قرار می دهد. این ژن ها از طریق استفاده از ناقل های ویروس به سلول های ایمنی منتقل می شوند. GenScript ProBio دارای یک توسعه فرآیند ناقل ویروس با کیفیت بالا و یک پلت فرم خدمات یک مرحله ای برای تولید GMP است که هر دو برای توسعه سلول و ژن درمانی ضروری هستند.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing سرطان خون. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong، مدیر عامل ACT Therapeutics، گفت: "ما آماده سازی پلتفرم ACT را برای ظهور جهانی از طریق مشارکت استراتژیک با GenScript ProBio تکمیل کرده ایم. ما توسعه درمان‌هایی را که سرطان‌های مقاوم و مقاوم به درمان را هدف قرار می‌دهند، تسریع خواهیم کرد.»
درباره GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
در راستای مأموریت «نوآوری از طریق همکاری»، GenScript ProBio متعهد است که به مشتریان کمک کند تا جدول زمانی توسعه داروهای بیولوژیکی را از کشف تا تجاری‌سازی کوتاه کنند، هزینه‌های تحقیق و توسعه را به میزان قابل توجهی کاهش داده و آینده‌ای سالم‌تر بسازند.
